NCT02650271CompletedPhase 3
Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC
Adjuvant Entecavir or Tenofovir for Hepatitis B Virus Related Hepatocellular Carcinoma After Curative Hepatic Resection
Source: ClinicalTrials.gov · Last updated 23 Jan 2024
Brief summary (registry, in English)
This study aims to compare the effect of antiviral therapy with entecavir or tenofovir for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Included patients will randomly divide into two groups.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (actual)
- First submitted
- 5 Jan 2016
- Start date
- 2 Feb 2021
- Primary completion date
- 25 Dec 2023
- Lead sponsor
- Guangxi Medical University
- NCT number
- NCT02650271
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 240
- From 2 Feb 2021 to the primary completion date, 25 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diagnosis of HCC was not confirmed by postoperative histopathology of surgical samples after surgery.
Other illness
- Anti-HCV(+)
Who the study is looking for
- Underwent hepatic resection.
- Diagnosis of HCC was confirmed by postoperative histopathology.
- Positive of HBsAg, HBeAg, or HBV DNA.
- Child-Pugh A or B liver function.
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University Coordinator of this site? Confirm its status | Nanning | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.